TG Therapeutics (TGTX) Launches Phase 1/2 Study of TGR-1202 and Carfilzomib in Relapsed or Refractory Lymphoma
Tweet Send to a Friend
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the launch of a Phase 1/2 study to evaluate the safety and efficacy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE